Cyclopharm Ltd (AU:CYC) — Market Cap & Net Worth
Market Cap & Net Worth: Cyclopharm Ltd (CYC)
Cyclopharm Ltd (AU:CYC) has a market capitalization of $41.81 Million (AU$59.10 Million) as of September 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #22670 globally and #820 in its home market, demonstrating a -3.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyclopharm Ltd's stock price AU$0.47 by its total outstanding shares 125734145 (125.73 Million). Also see how large is Cyclopharm Ltd's balance sheet for a full breakdown of the balance sheet.
Cyclopharm Ltd Market Cap History: 2015 to 2026
Cyclopharm Ltd's market capitalization history from 2015 to 2026. Data shows growth from $42.71 Million to $41.81 Million (0.73% CAGR). Also see cash efficiency ratio of Cyclopharm Ltd for how efficiently the company converts equity into cash flow.
Cyclopharm Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyclopharm Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Cyclopharm Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.70x
Cyclopharm Ltd's market cap is 2.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $75.78 Million | $14.39 Million | $891.37K | 5.27x | 85.02x |
| 2017 | $80.84 Million | $13.19 Million | -$1.52 Million | 6.13x | N/A |
| 2018 | $94.96 Million | $13.40 Million | -$35.46K | 7.08x | N/A |
| 2019 | $102.25 Million | $14.08 Million | -$2.91 Million | 7.26x | N/A |
| 2020 | $218.69 Million | $14.68 Million | -$6.04 Million | 14.90x | N/A |
| 2021 | $144.18 Million | $17.70 Million | -$5.04 Million | 8.14x | N/A |
| 2022 | $103.53 Million | $23.22 Million | -$6.61 Million | 4.46x | N/A |
| 2023 | $171.26 Million | $26.34 Million | -$4.70 Million | 6.50x | N/A |
| 2024 | $141.01 Million | $27.57 Million | -$13.20 Million | 5.11x | N/A |
| 2025 | $87.19 Million | $32.33 Million | -$17.22 Million | 2.70x | N/A |
Competitor Companies of CYC by Market Capitalization
Companies near Cyclopharm Ltd in the global market cap rankings as of September 21, 2026. Review tangible net worth ratio of Cyclopharm Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cyclopharm Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Cyclopharm Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Cyclopharm Ltd's market cap moved from $42.71 Million to $ 41.81 Million, with a yearly change of 0.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$41.81 Million | -52.04% |
| 2025 | AU$87.19 Million | -38.17% |
| 2024 | AU$141.01 Million | -17.66% |
| 2023 | AU$171.26 Million | +65.42% |
| 2022 | AU$103.53 Million | -28.19% |
| 2021 | AU$144.18 Million | -34.07% |
| 2020 | AU$218.69 Million | +113.89% |
| 2019 | AU$102.25 Million | +7.67% |
| 2018 | AU$94.96 Million | +17.46% |
| 2017 | AU$80.84 Million | +6.68% |
| 2016 | AU$75.78 Million | +77.42% |
| 2015 | AU$42.71 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Cyclopharm Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.81 Million USD |
| MoneyControl | $41.81 Million USD |
| MarketWatch | $41.81 Million USD |
| marketcap.company | $41.81 Million USD |
| Reuters | $41.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more